San Carlos, California-based Biomea Fusion (Nasdaq: BMEA) reported Phase I results for BMF-650, an oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), showing mean Day 29 weight reductions of 1.5% to 3.2% across four outpatient multiple ascending dose cohorts versus 0.1% for pooled placebo, with no severe or serious treatment-emergent adverse events across 40 active-dose participants over four weeks. A fifth cohort conducted under confinement showed mean weight loss of 6.1% with BMF-650, but the two placebo participants experienced similar reductions. Biomea said confinement appeared to affect eating behavior, limiting interpretation of the drug’s weight-loss effect in that cohort.
Gastrointestinal events across all active cohorts included nausea in 17.5%, vomiting in 7.5%, constipation in 10%, and diarrhea in 5% of participants, all mild or moderate, with no dose modifications or discontinuations and no ALT or AST elevations. In the confined cohort, participants received 200 mg daily for one week followed by 400 mg daily for three weeks, supporting further investigation of simpler dose escalation. Additional clinical development requires longer-term toxicology studies. Biomea plans to continue that work while seeking a strategic partnership, potentially including licensing for late-stage development and commercialization. The firm's primary development focus remains on the irreversible covalent menin inhibitor icovamenib (formerly BMF-219) in diabetes.
BMF-650’s proposed differentiation is an oral GLP-1 treatment that could require fewer dose-escalation steps while limiting gastrointestinal adverse effects. The four-week findings support further testing of that approach but do not establish a tolerability or efficacy advantage over other GLP-1 therapies.
Access the AllSci platform to explore the science behind the news.
Spot something wrong? Report an issue with this article